Lori Bjornson, NP
Family · Sandusky, MINPI 1992874077
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 431 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $6,045 and has fallen 84.3% since, to $947 in 2025. Among family clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 431 payments — averaging $41.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$2K
- AbbVie$2K
- Alkermes, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- plus $5K from 15 others
What the payments were for
- Food & beverage$17,43798%
- Education$3102%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 39 | $2,394 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 62 | $2,270 |
| Johnson & Johnson | 37 | $2,101 |
| AbbVie | 61 | $2,011 |
| Alkermes, Inc. | 58 | $1,998 |
| Otsuka America Pharmaceutical, Inc. | 29 | $1,623 |
| Neurocrine Biosciences, Inc. | 23 | $1,137 |
| Axsome Therapeutics, Inc. | 15 | $1,123 |
| Indivior Inc. | 38 | $657 |
| Vanda Pharmaceuticals Inc. | 26 | $512 |
| Supernus Pharmaceuticals, Inc. | 4 | $498 |
| Lundbeck LLC | 19 | $288 |
| Corium, LLC | 4 | $251 |
| Noven Pharmaceuticals, Inc. | 2 | $249 |
| Tris Pharma Inc | 2 | $229 |
| Idorsia Pharmaceuticals US Inc | 2 | $135 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $85 |
| Neuronetics, Inc. | 2 | $39 |
| Noven Therapeutics, LLC | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,319
- CAPLYTA$1,581
- ARISTADA$1,364
- REXULTI$1,067
- Austedo XR$1,053
- INGREZZA$869
- VRAYLAR$825
- Auvelity$697
- INVEGA SUSTENNA$594
- QELBREE$498
- AUSTEDO$482
- UZEDY$342
- ARISTADA INITIO$341
- Xelstrym$249
- SPRAVATO$247
- ABILIFY MAINTENA$230
- Quillichew ER$229
- Quillivant$229
- Dyanavel XR$229
- Azstarys$214
How this compares
$17,747 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 11 | $37,628 |
| CaplytaLumateperone Tosylate | 19 | $32,979 |
| VraylarCariprazine Hcl | 15 | $22,139 |
| Aripiprazole | 24 | $2,676 |
| Buspirone Hcl | 42 | $1,021 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 27 | $1,001 |
| Quetiapine Fumarate | 58 | $955 |
| Haloperidol Decanoate | 11 | $559 |
| Trazodone Hcl | 34 | $460 |
| Mirtazapine | 18 | $437 |
| Ziprasidone Hcl | 12 | $431 |
| Lamotrigine | 38 | $429 |
| Duloxetine Hcl | 12 | $345 |
| Fluoxetine Hcl | 22 | $340 |
| Olanzapine | 19 | $315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada | $1,998 | $37,62811 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,270 | $32,97919 claims |
| AbbVieVraylar | $2,011 | $22,13915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Sandusky
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.